GlobeNewswire by notified

Nyxoah Strengthens its Executive Leadership Team

Share

Nyxoah Strengthens its Executive Leadership Team
Francis Kim appointed as Chief Regulatory and Quality Officer

Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah’s Global Regulatory and Quality departments.

Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector. Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market.

“Nyxoah is entering the most exciting time in the Company’s history, with data from the DREAM U.S. pivotal study in early 2024, followed by submission of the final module in our modular PMA and FDA approval expected by the end of the year. I am excited having someone with Francis’ regulatory and quality experience joining Nyxoah at this important time, and I look forward to continued investments as we prepare to for a U.S. market entrance,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ensurge Micropower ASA - Registration of Share Capital Increase26.2.2024 12:15:41 CET | Press release

Oslo, 26 February 2024 Reference is made to the announcement by Ensurge Micropower ASA (the "Company") on 20 February 2024 regarding a successful private placement of shares ("Private Placement"), through an allocation of 233,468,885 new shares for total gross proceeds of NOK 58,367,221.25. The share capital increase has now been duly registered in the Register of Business Enterprises. Following the share capital increase, the Company's share capital is NOK 269,315,774.30 divided into 2,693,157,743 shares, each share having a par value of NOK 0.10. About Ensurge Micropower: Ensurge is Energizing Innovation (TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.2.2024 12:10:00 CET | Press release

Company Announcement No. 10/2024 Copenhagen, 26 February 2024 Transactions in connection with share buy-back programme On 10 November 2023, Scandinavian Tobacco Group A/S announced that a share buy-back programme of an aggregated value of up to DKK 850 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the programme will be conducted in accordance with Regulation No. 596/2014 of the Euro-pean Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 30/2023. The share buy-back programme will end no later than 28 February 2025. The following transactions have been executed from

Novo Nordisk A/S - share repurchase programme26.2.2024 12:02:48 CET | Press release

Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024. Since the announcement 19 February 2024, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement394,500327,673,06019 February 202442,500855.9136,376,12820 February 202443,000855.3936,781,82921 February 202443,000829.8435,683,11022 February 202443,000848.4136,481,7

Calibre Intercepts High Grade Gold Mineralization at the Limon Mine Complex, Proximal to the Limon Processing Plant; Drilling Intersects Include 68.72 g/t Gold Over 2.0 Metres and 18.68 g/t Gold Over 6.0 Metres26.2.2024 12:00:05 CET | Press release

VANCOUVER, British Columbia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the "Company" or "Calibre") is pleased to announce exciting drill results from its 2023 resource expansion and infill program at the Tigra, Limon Norte and Pozo Bono open pit deposits located next to the Limon processing plant. These high-grade intercepts combined with the recent positive news from the Panteon VTEM Gold Corridor, demonstrate that the entire Limon district remains open for expansion and discovery. Drill intercept highlights from the Tigra, Limon Norte and Pozo Bono targets include: 68.72 g/t Au over 2.0 metres Estimated True Width (“ETW”) and 16.49 g/t Au over 5.9 metres ETW including 26.71 g/t Au over 3.5 metres ETW in Hole LIM-23-4875;18.68 g/t Au over 5.9 metres ETW including 55.68 g/t Au over 2.0 metres ETW in Hole LIM-23-4876;9.26 g/t Au over 5.0 metres ETW including 17.10 g/t Au over 2.6 metres ETW in Hole LIM-23-4858;12.85 g/t Au over 4.2 metres ETW inclu

Cargotec announces positive results from the written procedures for its senior unsecured notes due 2025 and 202626.2.2024 12:00:00 CET | Press release

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 26 FEBRUARY 2024 AT 1:00 P.M. (EET) Cargotec announces positive results from the written procedures for its senior unsecured notes due 2025 and 2026 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SOUTH AFRICA, JAPAN, NEW ZEALAND OR SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR BUY ANY OF THE SECURITIES DESCRIBED HEREIN. Cargotec Corporation (“Cargotec”) announced on 8 February 2024 the commencement of the written procedures (the “Written Procedures”) and approached the holders of its EUR 100,000,000 1.250 per cent senior unsecured notes due 2025 (ISIN: FI4000399688) (the “2025 Notes”) and EUR 150,000,000 1.625 per cent senior unsecured notes due 2026 (ISIN: FI4000399696) (

HiddenA line styled icon from Orion Icon Library.Eye